FOLH1B抗体;FOLH1B Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P11770(FOLH1B Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P11770(FOLH1B Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The FOLH1B antibody targets the FOLH1B protein, a member of the folate hydrolase (FOLH) family, also known as prostate-specific membrane antigen (PSMA) or glutamate carboxypeptidase II (GCPII). FOLH1B is a splice variant of the FOLH1 gene, sharing structural similarities with the well-characterized FOLH1/PSMA protein, including a transmembrane domain and enzymatic activity. It functions as a type II transmembrane glycoprotein with carboxypeptidase activity, involved in folate digestion, neuropeptide processing, and possibly cell signaling.

FOLH1B has garnered attention due to its restricted overexpression in certain cancers, particularly prostate cancer, where it serves as a biomarker and therapeutic target. Unlike FOLH1/PSMA, FOLH1B’s expression profile and biological roles remain less defined, though studies suggest it may contribute to tumor progression or metastasis. Antibodies against FOLH1B are primarily used in research to elucidate its expression patterns, physiological functions, and pathological implications. They also hold potential for diagnostic applications (e.g., immunohistochemistry) and therapeutic strategies, such as antibody-drug conjugates or radioimmunotherapy targeting PSMA-related malignancies. However, cross-reactivity with FOLH1/PSMA requires careful validation to ensure specificity in experimental or clinical settings. Ongoing research aims to clarify its distinct roles and optimize FOLH1B-targeted interventions.